China SXT Pharmaceuticals, Inc.
SXTCHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeHeadquartered within the healthcare sector, China SXT Pharmaceuticals, Inc. focuses on Drug Manufacturers - Specialty & Generic services and products. China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company carries a $425K market cap, placing it firmly in the micro-cap category. The company offers Advanced TCMP, including Directly-Oral-TCMP, and After-Soaking-Oral TCMP; Fine TCMP and Regular TCMP products; and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen.
Market Cap
$424,657
Beta
1.86
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-73040.00
EPS (Fwd)
—
ROE
-27.5%
ROA
-15.8%
Cash
$28.3M
Total Debt
$1.1M
Free CF
-$4.7M
52W Change
-100.0%
Annual Financials
Cash vs Debt
Where SXTC stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, SXTC finished 99.88% below its 150-day moving average ($94.02) and 99.98% below its 200-day moving average ($690.58). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SXTC overbought or oversold?
At the October 20, 2026 close, SXTC's RSI(14) was 28.8, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $28.3M in cash and $1.1M in debt, SXTC maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$4.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -27.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $2.0M (2023) to $1.1M (2026), a 42% decline worth watching.
With a beta above 1.5, SXTC tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, SXTC has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for China SXT Pharmaceuticals, Inc. and its sector.